Can Pan-Immune Inflammation Value and Systemic Inflammatory Response Index be Used Clinically to Predict Inflammation in Patients with Non-Small Cell Lung Cancer?
Selen Karaoglanoglu1, Huseyin Erdal2, Muge Karaoglanoglu Sonmez31Department of Pulmonology, Faculty of Medicine, Ordu University Training and Research Hospital, Ordu, Türkiye Department of Pulmonology, Faculty of Medicine, Ordu University Training and Research Hospital, Ordu, Türkiye, 2Department of Medical Genetics, Aksaray University, Faculty of Medicine, Aksaray, Türkiye, 3Division of Medical Oncology, Ordu State Hospital, Ordu, Türkiye Division of Medical Oncology, Ordu State Hospital, Ordu, Türkiye
Objectives: Lung cancer is one of the most cancer type with the highest rate of cancer-related deaths in worldwide. Chronic inflammation has been associated with many diseases, including cancer, and the immune inflammatory response plays an important role in cancer patients. The aim of the study is to investigate the role of whether the panimmune-inflammation value (PIV) and the systemic inflammatory response index (SIRI) are effective in predicting nonsmall lung cancer patients. Methods: In this retrospective case-control study, eighty-four patients and 71 healthy controls followed in Ordu State Hospital, Department of Medical Oncology from January 2020- to January 2023 were included. Results: White Blood Cell, Neutrophil, Hemoglobin , RDW, CRP were statistically significant between the study groups (p<0.05). A statistically significant difference was found between SII, SIRI, PIV, NLR, LMR and dNLR indices between the case and healthy subjects (p<0.05). However, there was no significant difference in PLR levels between the groups (p>0.05). Conclusion: We indicated that SIRI and PIV could be novel cost-effective biomarkers and treatment response precursors in patients with NSCLC. Keywords: Non-small cell lung cancer, Inflammation, Systemic inflammatory response index, Pan-immune-inflammation value
Cite This Article
Karaoglanoglu S, Erdal H, Sonmez M. Can Pan-Immune Inflammation Value and Systemic Inflammatory Response Index be Used Clinically to Predict Inflammation in Patients with Non-Small Cell Lung Cancer?. EJMI. 2024; 8(1): 54-57
Corresponding Author: Huseyin Erdal